The FDA has approved Pyrukynd (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. The Food and Drug Administration (FDA) has approved Pyrukynd ® (mitapivat) ...

A rival company's trial results had a negative impact on Agios' stock this week.

Findings showed 28.1% of patients treated with mitapivat achieved a TRR vs 11.8% of patients who received placebo. A phase 3 trial evaluating mitapivat in pediatric patients with pyruvate kinase ...

Researchers from the University of Seville have participated in research to identify the molecular details of the regulation of an enzyme essential for sugar metabolism and closely linked to cell ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.

Glycolysis, the ancient and universal pathway of breaking down glucose, is more than just a source of energy—it’s a cornerstone of life’s chemistry. From its ten precisely orchestrated steps to its ...

(RTTNews) - Agios Pharmaceuticals Inc. (AGIO), said on Friday that the FDA has approved Pyrukynd for the treatment of hemolytic anemia in adults with pyruvate kinase or PK deficiency, a rare, ...